1. Prommer E. Olanzapine: palliative medicine update. Am J Hosp Palliat Care 2013;30:75-82. PMID:
22495793.
2. Kelly DL, Richardson CM, Yu Y, Conley RR. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum Psychopharmacol 2006;21:393-398. PMID:
16850522.
3. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Kirshner MA, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006;88:63-72. PMID:
16928430.
4. Rege S, Lafferty T. Life-threatening constipation associated with clozapine. Australas Psychiatry 2008;16:216-219. PMID:
18568631.
5. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 1999;37:107-122. PMID:
10227113.
6. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, Nelapp NW, Wong DT, et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 1997;58(Suppl 10):28-36. PMID:
9265914.
7. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001;61:111-161. PMID:
11217867.
8. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000;95:2698-2709. PMID:
11051338.
9. Tamir H, Payette RF, Huang YL, Liu KP, Gershon MD. Human serotonectin: a blood glycoprotein that binds serotonin and is associated with platelets and white blood cells. J Cell Sci 1985;73:187-206. PMID:
4019592.
10. Sikander A, Rana SV, Prasad KK. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin Chim Acta 2009;403:47-55. PMID:
19361459.
11. Bymaster FP, Falcone JF, Bauzon D, Kennedy JS, Schenck K, Delapp NW, et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 2001;430:341-349. PMID:
11711053.
12. Stasi C, Bellini M, Bassotti G, Blandizzi C, Milani S. Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol 2014;18:613-621. PMID:
24425100.
13. Kerckhoffs AP, Ter Linde JJ, Akkermans LM, Samsom M. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil 2008;20:900-907. PMID:
18363639.
14. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004;126:1657-1664. PMID:
15188158.
15. Costedio MM, Hyman N, Mawe GM. Serotonin and its role in colonic function and in gastrointestinal disorders. Dis Colon Rectum 2007;50:376-388. PMID:
17195902.
16. He WQ, Peng YJ, Zhang WC, Lv N, Tang J, Chen C, et al. Myosin light chain kinase is central to smooth muscle contraction and required for gastrointestinal motility in mice. Gastroenterology 2008;135:610-620. PMID:
18586037.
17. Murthy KS. Signaling for contraction and relaxation in smooth muscle of the gut. Annu Rev Physiol 2006;68:345-374. PMID:
16460276.
18. Hu W, Feng P. Myosin light chain kinase is involved in the mechanism of gastrointestinal dysfunction in diabetic rats. Dig Dis Sci 2012;57:1197-1202. PMID:
22302242.
19. Umer A, Lugowska H, Sein-Anand J, Rekowski P, Ruczynski J, Petrusewicz J, et al. The contractile effects of several substituted short analogues of porcine galanin in isolated rat jejunal and colonic smooth muscle strips. Pharmacol Res 2005;52:283-289. PMID:
15946852.
20. Xiong YJ, Chen DP, Lv BC, Liu FF, Wang L, Lin Y. The characteristics of genistin-induced inhibitory effects on intestinal motility. Arch Pharm Res 2013;36:345-352. PMID:
23435915.
21. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, Mckinzie DL. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1125-1143. PMID:
14642972.
22. Farthing MJ. Irritable bowel syndrome: new pharmaceutical approaches to treatment. Baillieres Best Pract Res Clin Gastroenterol 1999;13:461-471. PMID:
10580922.
23. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996;16:2352-2364. PMID:
8601815.
24. Spiller R. Serotonin and GI clinical disorders. Neuropharmacology 2008;55:1072-1080. PMID:
18687345.
25. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130:34-43. PMID:
16401466.
26. Derkach V, Surprenant A, North RA. 5-HT3 receptors are membrane ion channels. Nature 1989;339:706-709. PMID:
2472553.
27. Guarino M, Cheng L, Cicala M, Ripetti V, Biancani P, Behar J. Progesterone receptors and serotonin levels in colon epithelial cells from females with slow transit constipation. Neurogastroenterol Motil 2011;23:575-e210. PMID:
21481100.
28. Costedio MM, Coates MD, Brooks EM, Glass LM, Ganguly EK, Blaszyk H, et al. Mucosal serotonin signaling is altered in chronic constipation but not in opiate-induced constipation. Am J Gastroenterol 2010;105:1173-1180. PMID:
20010921.
29. Gustafsen J, Lendorf A, Raskov H, Boesby S. Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial. Scand J Gastroenterol 1986;21:816-818. PMID:
3535008.
30. Kawamura H, Arai M, Togari A. Inhibitory effect of chlorpromazine on RANKL-induced osteoclastogenesis in mouse bone marrow cells. J Pharmacol Sci 2011;117:54-62. PMID:
21869564.
31. Gonzalez-Andrade M, Mata R, Madariaga-Mazon A, Rodriguez-Sotres R, Del PL, Sosa-Peinado A. Importance of the interaction protein-protein of the CaM-PDE1A and CaM-MLCK complexes in the development of new anti-CaM drugs. J Mol Recognit 2013;26:165-174. PMID:
23456740.